Artificial Intelligence and Machine Learning in the Development of Vaccines and Immunotherapeutics Yesterday, Today, and Tomorrow

• URL: http://arxiv.org/abs/2506.12185v1
• Date: Fri, 13 Jun 2025 19:20:43 GMT
• Title: Artificial Intelligence and Machine Learning in the Development of Vaccines and Immunotherapeutics Yesterday, Today, and Tomorrow
• Authors: Elhoucine Elfatimi, Yassir Lekbach, Swayam Prakash, Lbachir BenMohamed,
• Abstract summary: In the past, the development of vaccines and immunotherapeutics relied heavily on trial-and-error experimentation and extensive in vivo testing.<n>The future of AI and deep learning points toward replacing animal preclinical testing of drugs, vaccines, and immunotherapeutics with computational-based models.<n>This may result in a fast and transformative shift for the development of personal vaccines and immunotherapeutics against infectious pathogens and cancers.
• Score: 0.0
• License: http://creativecommons.org/licenses/by/4.0/
• Abstract: In the past, the development of vaccines and immunotherapeutics relied heavily on trial-and-error experimentation and extensive in vivo testing, often requiring years of pre-clinical and clinical trials. Today, artificial intelligence (AI) and deep learning (DL) are actively transforming vaccine and immunotherapeutic design, by (i) offering predictive frameworks that support rapid, data-driven decision-making; (ii) increasingly being implemented as time- and resource-efficient strategies that integrate computational models, systems vaccinology, and multi-omics data to better phenotype, differentiate, and classify patient diseases and cancers; predict patients' immune responses; and identify the factors contributing to optimal vaccine and immunotherapeutic protective efficacy; (iii) refining the selection of B- and T-cell antigen/epitope targets to enhance efficacy and durability of immune protection; and (iv) enabling a deeper understanding of immune regulation, immune evasion, immune checkpoints, and regulatory pathways. The future of AI and DL points toward (i) replacing animal preclinical testing of drugs, vaccines, and immunotherapeutics with computational-based models, as recently proposed by the United States FDA; and (ii) enabling real-time in vivo modeling for immunobridging and prediction of protection in clinical trials. This may result in a fast and transformative shift for the development of personal vaccines and immunotherapeutics against infectious pathogens and cancers.

Related papers

• Harnessing Preference Optimisation in Protein LMs for Hit Maturation in Cell Therapy [0.5315454965484603]
  Cell and immunotherapy offer transformative potential for treating diseases like cancer and autoimmune disorders by modulating the immune system.<n>The development of these therapies is resource-intensive, with the majority of drug candidates failing to progress beyond laboratory testing.<n>Recent advances in machine learning have revolutionised areas such as protein engineering, applications in immunotherapy remain limited due to the scarcity of large-scale, standardised datasets and the complexity of cellular systems.
  arXiv  Detail & Related papers  (2024-12-02T11:21:58Z)
• Immunogenicity Prediction with Dual Attention Enables Vaccine Target Selection [6.949493332885247]
  We introduce VenusVaccine, a novel deep learning solution for predicting immunogenicity in vaccines.<n>We also compile the most comprehensive immunogenicity dataset to date, encompassing over 7000 antigen sequences, structures, and immunogenicity labels from bacteria, virus, and tumor.<n>Our work provides an effective tool for vaccine design and sets valuable benchmarks for future research.
  arXiv  Detail & Related papers  (2024-10-03T16:33:35Z)
• ADIOS: Antibody Development via Opponent Shaping [49.26728828005039]
  Anti-viral therapies are typically designed to target only the current strains of a virus.<n>However, therapy-induced selective pressures drive the emergence of new viral strains.<n>This evolutionary response presents an opportunity: our therapies could both defend against and actively influence viral evolution.
  arXiv  Detail & Related papers  (2024-09-16T14:56:27Z)
• AI driven B-cell Immunotherapy Design [0.0]
  The effectiveness of antigen neutralisation and elimination hinges upon the strength, sensitivity, and specificity of the paratope-epitope interaction. In recent years, artificial intelligence and machine learning methods have made significant strides, revolutionising the prediction of protein structures and their complexes. This review focuses on the progress of machine learning-based tools and their frameworks in the domain of B-cell immunotherapy design.
  arXiv  Detail & Related papers  (2023-09-03T09:14:10Z)
• Agent-Based Model: Simulating a Virus Expansion Based on the Acceptance of Containment Measures [65.62256987706128]
  Compartmental epidemiological models categorize individuals based on their disease status. We propose an ABM architecture that combines an adapted SEIRD model with a decision-making model for citizens. We illustrate the designed model by examining the progression of SARS-CoV-2 infections in A Coruna, Spain.
  arXiv  Detail & Related papers  (2023-07-28T08:01:05Z)
• Dense Feature Memory Augmented Transformers for COVID-19 Vaccination Search Classification [60.49594822215981]
  This paper presents a classification model for detecting COVID-19 vaccination related search queries. We propose a novel approach of considering dense features as memory tokens that the model can attend to. We show that this new modeling approach enables a significant improvement to the Vaccine Search Insights (VSI) task.
  arXiv  Detail & Related papers  (2022-12-16T13:57:41Z)
• Evaluating vaccine allocation strategies using simulation-assisted causal modelling [7.9656669215132005]
  Early on during a pandemic, vaccine availability is limited, requiring prioritisation of different population groups. We develop a model to retrospectively evaluate age-dependent counterfactual vaccine allocation strategies against the COVID-19 pandemic. We compare Israel's implemented vaccine allocation strategy in 2021 to counterfactual strategies such as no prioritisation, prioritisation of younger age groups or a strict risk-ranked approach.
  arXiv  Detail & Related papers  (2022-12-14T14:24:17Z)
• Data-Centric Epidemic Forecasting: A Survey [56.99209141838794]
  This survey delves into various data-driven methodological and practical advancements. We enumerate the large number of epidemiological datasets and novel data streams that are relevant to epidemic forecasting. We also discuss experiences and challenges that arise in real-world deployment of these forecasting systems.
  arXiv  Detail & Related papers  (2022-07-19T16:15:11Z)
• Constrained Submodular Optimization for Vaccine Design [1.7622426179653559]
  Genetic variability makes it difficult to design peptide vaccines that provide widespread immunity in vaccinated populations. We introduce a framework for evaluating and designing peptide vaccines that uses probabilistic machine learning models. We demonstrate its ability to produce designs for a SARS-CoV-2 vaccine that outperform previous designs.
  arXiv  Detail & Related papers  (2022-06-16T17:40:54Z)
• COVID-Net Biochem: An Explainability-driven Framework to Building Machine Learning Models for Predicting Survival and Kidney Injury of COVID-19 Patients from Clinical and Biochemistry Data [66.43957431843324]
  We introduce COVID-Net Biochem, a versatile and explainable framework for constructing machine learning models. We apply this framework to predict COVID-19 patient survival and the likelihood of developing Acute Kidney Injury during hospitalization.
  arXiv  Detail & Related papers  (2022-04-24T07:38:37Z)
• MIA-Prognosis: A Deep Learning Framework to Predict Therapy Response [58.0291320452122]
  This paper aims at a unified deep learning approach to predict patient prognosis and therapy response. We formalize the prognosis modeling as a multi-modal asynchronous time series classification task. Our predictive model could further stratify low-risk and high-risk patients in terms of long-term survival.
  arXiv  Detail & Related papers  (2020-10-08T15:30:17Z)
• Accelerating Antimicrobial Discovery with Controllable Deep Generative Models and Molecular Dynamics [109.70543391923344]
  CLaSS (Controlled Latent attribute Space Sampling) is an efficient computational method for attribute-controlled generation of molecules. We screen the generated molecules for additional key attributes by using deep learning classifiers in conjunction with novel features derived from atomistic simulations. The proposed approach is demonstrated for designing non-toxic antimicrobial peptides (AMPs) with strong broad-spectrum potency.
  arXiv  Detail & Related papers  (2020-05-22T15:57:58Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.